Abstract: Although Hox genes have been identified as master regulatory genes controlling embryonic development, an alternative view on the role of the Hox gene network suggests that it regulates crucial processes at cellular level in eukaryotic organisms. The Hox network acts at the nuclear cell level as a decoding system for external inductive signals to activate specific genetic programs. Cancer can be considered as an anomalous structure growing inside the human body and following, from an architectural viewpoint, the rules controlling body shape as occurs during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and three-dimensionality of tissues and organs and, furthermore, that specific HOX genes or groups of genes are implicated in the neoplastic alterations of organs and tissues such as kidney, colon, lung, skin, bladder, breast, prostate. Despite our limited understanding of the mechanisms involved, it has already been possible to identify the specific HOX genes perturbed in certain types of human cancers with greater benefit for cancer patients than for better known oncogenes. Here we foresee the start of clinical trials with the purpose of targeting specific HOX genes in order to achieve a therapeutic effect in cancer patients.
INTRODUCTION
Genes involved in the same gene program on the human genome are often located in physical contiguity along the same chromosomal region (beta-globin Loci Controlling Regions = LCR [1] ; Hox D Global Controlling Region = GCR [2] ) to be transcribed together. In the absence of physical contiguity, when genes acting on the same gene program are active, they move their DNA to transcription factories. Transcription factories are particular sites in the cell nucleus (often in the nuclear matrix) where genes transcribed together are grouped by nuclear matrix-attachment region (MAR) proteins (Satb1 and Satb2) [3] . Specific transcription factors are responsible for connecting transcription factories to the general transcription machinery containing RNA polymerase II and general transcription factors [4] . The ultimate goal of oncogenes and oncosuppressor genes is to modify the way gene programs are executed through dysregulation of their transcription. Transcription factories and transcription factors are thus crucial in eukaryotic cells to both regulate phenotype identity as well as to induce phenotype alterations (cancer).
The identification of the molecular mechanisms involved in determining both phenotype cell identity and spatiotemporal localization of each mammalian cell (cellular memory) is one of the leading subjects of modern biology [5] . The control of gene programs regulating cellular memory is mostly attributed to the Polycomb genes (PcG), responsible for keeping the expression of HOX genes silent during normal development, and to Tritorax genes (TrxG) which maintain HOX gene expression patterns within the appropriate spatial domain [6] . These gene families (PcG, TrxG and HOX) are thus able to control patterning during normal development as well as to regulate stem cell fates and differentiation, generating each of the three hundred cell phenotypes present in the human body. Despite their role in the DNA-chromatin interaction (histone modifications and DNA methylations), PcG, TrG and HOX genes are involved in cell proliferation and cancer.
Class I Homeobox genes (HOX genes) play a particular role among homeobox-containing genes, a superfamily of transcription factors mostly involved in embryonic development and characterized by a 183 bp DNA sequence originally identified in the homeotic genes of Drosophila [7] . In mice (Hox genes) and humans (HOX genes) there are at least 39 genes organized in four genomic clusters (Fig. 1) . On the basis of sequence similarity and position on the locus, corresponding genes in the four clusters can be aligned with each other and with genes of the HOM-C complex of Drosophila in 13 paralogous groups [8] . During mammalian development, Hox gene expression controls the identity of various regions along the body axis, from the branchial area through to the tail [9] . This is achieved according to the rules of temporal and spatial co-linearity, with 3' Hox genes expressed early in development and controlling anterior regions, followed by progressively more 5' genes expressed later and controlling more posterior regions [10] . In particular, 3' Hox genes in groups 1 to 4 (cervical) primarily control the development of the branchial area and the rhomboencephalon, the embryonic region corresponding to the hindbrain [11] . Central Hox genes in groups 5 to 8 control the thoracic portion of the body, whereas 5' Hox genes in groups 9 to 13 control the lumbo-sacral region. The HOX gene network comprises the most repeat-poor regions of the human genome [12] , thus representing the only physically identifiable genomic network. Hox and homeobox genes are also expressed in normal adult human organs [13] .
It has been postulated that determination of phenotype cell identity is the primary function of the Hox gene network and is distinct from the consequent function of controlling body segment identity [14, 15, 16] . According to this view, the Hox network acts at the nuclear level of eukaryotic cells as a decoding system for external inductive signals that allow the activation of specific genetic programs. Specific genes in the network act as signal collectors (from growth factors and signal transduction pathways). These signals are then transferred to key genes in the decoding network (decoder genes may vary in different cell phenotypes). Through transmitter genes, a response is sent outside the Hox network. This activates specific programs of effector genes (morphogenetic molecules, cell-cycle related proteins, apoptotic pathway) in order to achieve the changes induced by the signal received [17] . Multiple cellular processes are regulated through the Hox network: the acquisition and maintenance of spatial and temporal cell allocation; the establishment of cell identity, achieving specific cell phenotypes through the decoding of microenvironment signals; the control of cell growth and proliferation through interaction with the cell-cycle and the apoptotic pathways; the process of cell-cell communication through cross-talk with morphogenetic molecules, growth factors and cytokines and signal transduction pathways; the antero-posterior patterning during embryonic development; the regulation of cell compartmentalisation and architectural organisation during morphogenesis and organognesis [18] .
A large body of literature has been produced on the role of the HOX gene network in tumour evolution, suggesting the involvement of HOX genes in several types of human cancers. In recent years, the increasing reliability of technologies for whole-genome RNA expression and the coupling of bioinformatics and gene expression has made it possible to conduct large scale screenings, in order to determine gene expression patterns for use in clinical evaluations. This has resulted in the acquisition of "HOX genes as emerging stars in cancer" [19] .
In this review we will describe, according to current data, how the HOX gene network acts in specific types of human solid cancers (breast, prostate, bladder, kidney) in order to show how specific HOX genes can be used as diagnostic and predictive tools in cancer research. Finally, given the involvement of the HOX network in malignant transformation and tumor progression, including invasion, metastasis and neo-angiogenesis, we will postulate the possibility that HOX genes could be potential molecular targets for selective cancer therapy.
BREAST CANCER
Locus A and C HOX genes are implicated in breast carcinomas: HOX A5 behaves as a transcriptional regulator of multiple target genes, two of which are p53 and the progesterone receptor [20] . HOX C6 has been detected in breast carcinomas as being able to contribute to breast cell phenotype through its interaction with other HOX genes (HOX B7) or by repressing their target genes. Increased HOX D3 expression has been connected to angiogenesis through the regulation of alpha v beta 3 integrin and urokinase plasminogen activator (u-PA).
We have recently reported the expression of the complete HOX gene network in normal human breast and in primary breast carcinomas in order to understand whether the HOX network is implicated in breast cancer evolution and to identify the specific HOX genes in the network that are primarily involved with breast tumorigenesis [21] . The HOX gene network displays an overall expression pattern characteristic of normal breast tissue. The expression of thoracic HOX genes is similar in normal and neoplastic breast tissue indicating that these genes may be involved in breast organogenesis. In contrast, cervical and lumbo-sacral HOX genes manifest altered expression in primary breast cancers with respect to normal breast, which supports their involvement in breast cancer progression. Specific HOX genes, such as HOX B2, HOX D3 and HOX D4 in the cervical part of the network and HOX D10, HOX A11 and HOX B13 in the lumbo-sacral part of the network, are, according to these results, good candidate genes to be tested in a large study In order to confirm their role in breast cancer progression. Tamoxifen significantly reduces tumour recurrence in early-stage estrogen-positive breast cancers. Approximately 40% of ER + breast cancers fail to respond or eventually develop resistance to tamoxifen, leading to disease progression. Current clinicopathological features including tumour stage and grade, and ERBB2 and EGFR expression fail to accurately identify individuals who are at risk for tumour recurrence. The literature has recently reported the gene expression profiling (22,000 genes) of tumours from 60 women uniformily treated with adjuvant tamoxifen monotherapy [22] . This cohort included 46% tamoxifen recerrences and 54% tamoxifen non recurrences with a 5-year follow-up-available after biopsy and matching of recurrence and nonrecurrence cases with respect to TNM staging [23] and tumour grade [24] . An initial screening pointed to the existence of statistically significant differences in gene expression between the primary breast cancers of tamoxifen nonrecurrences and recurrences through the identification of 19 differentially expressed genes. A more refined analysis using laser-capture microdissection (LCM) of tumour cells within each tissue section [25] identified 9 differentially expressed genes. Three genes were differentially expressed in both whole tissue sections and LCMs: HOX B13, the interleukin 17B receptor and EST A1240933. HOX B13 was hyper-expressed in tamoxifen recurrence cases, whereas IL17BR and A1240933 were hyper-expressed in tamoxifen nonrecurrence cases. These three genes, thus, predict the clinical outcome of patients treated with adjuvant tamoxifen. Due to the opposite patterns of expression between HOX B13 and IL17BR, tests were carried out to verify the possibility that the expression ratio of HOX B13 over IL17BR may be predictive of tamoxifen response, and the HOX B13:IL17BR ratio was compared to well-established prognostic factors for breast cancer, such as patient age, tumor size, grade, and lymph node status PGR and ERBB2 expression. The results demonstrated that the expression ratio of HOX B13:IL17BR is a strong independent predictor of treatment outcome in deciding adjuvant tamoxifen therapy.
BLADDER CANCER
Comparison between normal urothelium and bladder tumour has identified dramatic variations of expression in a block of three genes (HOX C4, HOX C5 and HOX C6) localized in the HOX C locus on the chromosome 12q13 and in the paralogous group 11 HOX genes, involved during normal development in the formation of the urogenital system [26] . In particular, the HOX C6 gene, is always silent in normal bladder but active in 100% of the 30 cases of TCC examined. The physical location of the HOX C locus on chromosome 12q13 is within a chromosomal region recently described as amplified in bladder cancer [27] . This region contains (in addition to the entire HOX C locus) around sixty genes, including those which play a better documented oncogenic role such as MDM2 (murine double minutes), CDK4 (cyclin-dependent kinase 4) and GLI (glioblastoma-associated oncogene). These genes also include those coding for the cytokeratins CK8 along with the cytokeratin genes CK1, CK 3, CK 4, CK5, CK6A and CK6B [28] . Furthermore, located in physical contiguity to the 3' end of the HOX C locus are the genes for CK7 and the basic hair Keratin 1 and 6, transcriptionally regulated by the HOX C13 gene [29] . Another group of cytokeratin genes is located on chromosome 17p21.3 [30] in physical contiguity to the HOX B locus. In bladder cancer, alteration of the expression of a series of CKs normally active in the urothelium, such as CK8, CK18, and CK 19, has been described, making it possible to suggest a distinction between TCCs through cytokeratin expression patterns [31] . In biology the concept of common functions performed by physically and/or evolutionarily contiguous genes is gaining increasing support [2] .
During normal development, paralogous group 11 HOX genes are involved in the formation of the posterior region, including the uro-genital system [32] (see kidney cancer section). The HOX A11 gene, active in most normal bladder tissue, tends to become silent in cancer tissue [26] . The HOX C11 gene, which is silent in normal urothelium, becomes active in almost all the TCC samples tested. Finally, the HOX D11 gene, always silent in normal bladder tissue, appears heterogeneously expressed in bladder cancer. It is thus possible to hypothesize a role for HOX C6 and paralogous group 11 HOX genes in the regulation of the cell phenotypes involved in urological carcinogenesis.
PROSTATE CANCER
Recently the gene expression patterns from 52 human prostate tumours and 50 normal prostate specimens, using oligonucleotide microarrays containing probes for approximately 12600 genes were studied in order to understand whether such patterns could be predictive of common clinical and pathological phenotypes relevant to treatment [33] . The analysis indicated that 317 genes were hyper-expressed in prostate tumour samples and 139 genes in normal prostate samples. The expression patterns of the 52 tumours were further analysed in order to predict differences in clinical behaviour among prostate cancers. No statistically significant gene expression correlation of the clinical and pathological features was observed with the exception of the Gleason score. A gene expression signature of GS was thus detectable: fifteen hyper-expressed and fourteen hypoexpressed genes correlate with GS and their expression is reproducible. While no single gene was statistically associated to recurrence, a 5 gene model predicts recurrence with 90% accuracy. The 5 genes are chromogranin A, plateletderived growth factor receptor (PDGFR ), HOX C6, inositol triphosphate receptor 3 (IPTR3) and sialyltransferase -1. These data support the notion that the clinical behaviour of prostate cancer is linked to underlying gene expression differences, detectable at the time of diagnosis. Thus, a 5 gene expression model alone accurately predicts patient outcome following prostatectomy and one of these genes is HOX C6, the gene reported to be inactive in 100% of bladder cancers [26] . Furthermore, the association of specific gene expression, such as PDGFR or HOX C6, to the clinical outcome raises the possibility that expression analysis may prove useful in selecting patients for emerging mechanism -based therapeutics.
In light of these observations we have recently investigated the involvement of the HOX gene network in neurendocrine differentiation of human advanced prostate cancer [34] by using a model of human prostate tumour evolution and including: (a) primary cultures of prostate fibroblasts, as for the mesenchymal compartment; (b) a non-tumorigenic prostate epithelial cell line (EPN); (c) three malignant cell lines generated from metastasis of prostate adenocarcinomas with different bodily localization: bone (PC3), brain (DU145), and lymph-node (LNCaP), and characterized by androgen independency (PC3 and DU145) or dependency (LNCaP). The expression patterns of the HOX gene network in these human prostate cell phenotypes, representing different stages of prostate physiology and prostate cancer progression, make it possible to discriminate between the different human prostate cell lines and to identify loci and paralogous groups harbouring the HOX genes mostly involved in prostate organogenesis and cancerogenesis.
cAMP is known to induce epithelial-neurocrine differenttiation in prostate cancer cells [35] . The effect of sustained intracellular level cAMP on the HOX gene network expression has been investigated: cAMP induces a substantial difference in the expression of the HOX gene network in the non-tumourigenic phenotype (EPN) with respect to malignant ones (PC3, DU145 and LNCaP) and makes it possible to distinguish prostate metastatic cell lines in a way corresponding to the presence of andogen-receptors, active in LNCaP and absent in PC3 and DU145 [36] .
In this cell system, exposure to cAMP mainly alters the expression of HOX genes situated on the HOX D locus and localized on chromosome 2q31-32. During embryonal development, Hox D genes play an important role in limb and digit generation [37] . In this same chromosomal area of the genome, a global control region has recently been identified upstream from the Hox D cluster, harbouring cisregulatory DNA elements able to coordinate the expression not only of Hox D genes and their immediate surroundings, but also of phylogenetically unrelated genes lying several hundred kilobases from one another [2] . Besides the Hox D13 gene involved in prostate morphogenic defects in mutant mice [38] , this chromosomal area houses the genes CREB1 and CREB2 (ATF2) cyclic AMP activating transcription factors as well as the cAMP sensor guanine nucleotide exchange factor II gene (cAMP-GEFII), specifically active in the developing brain and regulating exocytosis in secretory cells. Furthermore, this same chromosomal area also houses the prostate-specific androgenregulated gene PCGEM1, whose expression increases in high-risk prostate cancer patients [39] . PCGEM1 is a non coding RNA gene belonging to the microRNA family (miRNAs) involved in a number of important cell and developmental pathways. The chromosomal region 2q31-33 houses, in physical contiguity to PCGEM1, the genes neurexin-1 and NeuroD1. Neuronexins are polymorphic cell surface proteins coded by three genes (neuronexin 1, 2 and 3) expressed mostly in the brain and playing a role in cellcell interaction [40] . NeuroD1 belongs to the "atonal" family of transcription factors, responsible for regulating the generation of a protosensory organ in Drosophila [41] . Thus, the second messenger cAMP acts on a genomic region, molecularly coordinated with respect to epithelial-neuroendocrine conversion as it occurs along tumour progression of prostate adenocarcinomas, presumably connected to androgen dependency and prostate phenotype through PCGEM1 and locus D HOX genes. It has recently been reported that the chromosomal area upstream of the HOX D locus contains nonrepetitive non coding regions extremely conserved during 500 million years of evolution, which may constitute an important insight into the evolution of mechanisms regulating associated gene complexes [42] . In coupling nuclear architecture and gene activity, spatial positioning in the genome is a functionally highly relevant, physiological and global phenomenon [43, 44] .
We have selected one of the neurogenic genes located on the chromosomal area 2q31-33, Neuro D1, and tested the expression of its protein product along prostate cancer progression. The choice of Neuro D1 is supported by the observation that ectopic expression of Neuro D1 in Xenopus embryos causes conversion of epithelial cells into neurons [45] . Interestingly, NeuroD1 is actively expressed in vivo in advanced prostate cancers displaying a terminal stage of tumour differentiation as determined by an increased combined Gleason score [46] .
KIDNEY CANCER
The metanephric kidney architecture is created between the 5 th and 15 th weeks of human development. From the 16 th to the 23 rd weeks, following the filling in of the sulci between the lobes, the metanephroi increase their growth, without completing it or acquiring kidney functionality [47] . Around the 23 rd week of development, the foetal kidney starts to produce urine and continues to grow and acquire functions until birth. This process will be definitively completed during the first years of life [48] .
The molecular mechanisms involved in early kidney organogenesis require the expression, in the matanephric blastema, of paralogous group 11 Hox genes, Hox A11 and Hox D11 [49] , to induce the outgrowth of the ureteric bud from the Wolffian duct through the expression of several transcription factors (Wt1, Pax 2, Sall1, Fox C1 and Eya1) [50] [51] [52] [53] [54] , the nuclear protein formin [55] , the growth factors GDNF [56] and its tyrosine kinase receptor Ret [57] and coreceptor Gfr 1 [58] . Wnt signals are crucial inductors of kidney tubologenesis, as deduced by the Wnt4 mutant mice lacking epithelial-mesenchymal transition and tubulogenesis [59] .
The crucial role played by Hox genes in the epithelialmesechymal interaction during early kidney development is well established, with the expression of two of the three paralogous group 11 Hox genes, Hox A11 and Hox D11. Although single homozygous null mutation of either gene gives normal kidney, double mutants manifest hypoplasia of the kidneys and removal of the last Hox 11 paralogous gene, Hox C11, results in the complete loss of metanephric kidney induction [60] . Little is known on the involvement of paralogous group 11 Hox genes on late kidney organogenesis. Other lumbo-sacral Hox genes (Hox A13 and Hox D13) are involved during early morphogenesis of the terminal part of the gut and urogenital tract [61] .
A comparison of the HOX network expression patterns between foetal, adult normal and tumorous kidney identifies, in locus A, a decrease in the thoraco-cervical region of the network relative to the RCCs biopsies. Lumbo-sacral HOX D genes are all silent in foetal kidneys from the 15 th to the 22 nd week of development. HOX D9 and HOX D11 start to be expressed from the 23 rd week, and remain active until the 38 th developmental week. The expression of these genes can be temporally connected to kidney functions as the kidney starts functioning, for instance to produce urine, from the 23 rd week. HOX D9 and HOX D11 are constitutively expressed in normal adult human kidneys and are the only lumbo-sacral HOX D genes active in primary epithelial tubular kidney cells to prove that the function of these homeoproteins is performed in tubular epithelial kidney cells. HOX D9 and HOX D11 are inactive in 76% and 100%, respectively, of clear cell RCCs.
It has been suggested that, during tumour evolution, the gene profiles responsible for identifying specific cell phenotypes, undergo a de-differentiation programme towards early developmental stages. The patterns of lumbo-sacral HOX D gene expression in foetal kidneys (from the 15 th to the 22 nd week of development) overlap with the same patterns in clear cell RCCs suggesting that, in clear cell carcinomas of the kidney, the expression of lumbo-sacral HOX D genes marks a molecular de-differentiation process towards embryonic life.
HOX AND MECHANISMS
The mechanisms through which HOX genes act in normal cells and whose deregulation might be involved with tumor evolution are related to the function of this family of transcription factors in cell fate determination. HOX proteins interact with transcriptional coactivators (GCN5, p300/CBP, MOF) to increase access to target genes on DNA [62] . The complex of homeoproteins and coactivators act, in turn, on the general transcriptional machinery through the activity of a histone acetyltransferase (HAT) domain within the nucleosome core, facilitating and/or stabilizing access to target genes. Another histone modification, H3 K4 methylation, is connected with transcriptional activation in eukaryotic systems, Histone acetylation and H3 K4 methylation appear to interact with each other as demonstrated between Tritorax (TRX) and CBP in Drosophila [63] and MLL1 and CBP in human cells [64] . It has thus been proposed that HOX genes, instead of acting as transcriptional regulators, modulate acetyltransferase (HAT) and methyltransferase activities of coactivators [65] .
HOX AND THERAPY
The work carried out in recent years allows us to consider cancer as an anomalous structure growing inside the human body and following, from a cellular and architectural viewpoint, the rules controlling body shape during embryonic development. As a consequence of this viewpoint, it has been proposed that the whole HOX gene network is involved in controlling phenotype cell identity and the tridimensionality of tissues and organs. Furthermore, specific HOX genes or groups of genes are implicated in the neoplastic alterations of particular cell phenotypes in specific tissues and organs from kidney to colon, lung, thyroid, bladder, prostate, esophagus, lymphoid organs and skin. Furthermore, the deregulation of HOX gene expression and alterations in HOX genes have been most convincingly demonstrated in haematopoietic malignancies (this topic will not be covered in our review and interested readers are referred to more specialistic publications [66] ). Despite our limited understanding of the mechanisms involved, it has already been possible to identify: i) specific HOX genes perturbed in certain types of human cancers with greater benefits for cancer patients than for better known oncogenes (HOX C6 and prostate cancer, HOX B13 versus ERBB2 in breast cancers); ii) distinctive signatures with specific patterns of HOX gene expression in human leukemias [67] .
The identification of HOX gene deregulation in specific human tumor types suggests that the targeting of HOX genes for cancer therapy can be postulated. This is the consequence of the firm belief of an increased acknowledgment of the HOX gene function in cancer following a deeper understanding of DNA-chromatin interaction and fine transcriptional tuning of the gene programs involved in determining cell memory and spatio-temporal cell identity.
The identification of oncogenes, oncosuppressor genes and signaling molecules as targets in cancer therapy requires the correction of several protein alterations. The inhibition of proteins by small molecules is much more pharmacologically amenable. The inhibition of oncogenes, the stimulation of oncosuppressor genes, the limitation of the replicative potential, the regulation of apoptosis, and also the blocking of angiogenesis and of the metastatic process all require the repair of transcriptional alterations of several genes, of entire gene programs and of a series of signaling proteins to make the use of a single protein or a few proteins impossible. Acting directly on specific transcription factors also seems more feasible because their number is much lower than the number of oncogenes and oncosuppressor genes. The inhibition of transcription factors thus appears difficult although not impossible. Finally we propose to inhibit selective transcription, not general transcription as occurs with anthracycline used in clinical practice. Acting on specific targets implies some toxicity, but the advantage of blocking the growth of an invasive tumour outweighs the risk.
In our opinion, targeting HOX network genes out of all the transcription factors constitutes an dvantage because of: i) their ability to control antero-posterior patterning, organ distribution and phenotype cell identity; ii) the small number of specific transcription factors which could enable common therapeutic approaches for human tumor types connected through embryonic related phenotypes. A limited number of pharmacological agents could be able to interact with crucial HOX genes in the network which are responsible for playing crucial roles in several tumour phenotypes with common cellular characteristics. Completion of the human genome sequencing unveiled an estimated number of 35000 genes and their multiple RNA spliced variants. To fully exploit this information for targeted cancer therapy, high throughput genomic and proteomic technologies have been applied to identify a plethora of targets involved in the malignant phenotypes that need to be validated and prioritized as therapeutic targets. In theory, antisense oligonucleotide (ASO) and small interfering RNA (siRNA) molecules are ideal tools to serve the purpose of target validation and targeted therapy. These two major approaches could also be used in the targeting of HOX transcription factors in cancer. Other approaches such as dominant negative mutants and repressive transcription factors should be discarded due to the complex interaction of the homeoproteins with the machinery of general transcription.
ANTISENSE OLIGONUCLEOTIDES (ASO)
Antisense oligonucleotides are short, synthetic single strands of DNA complementary to target sequences (DNA or RNA) designed to specifically inhibit, through hybridization, the translational process of target gene transcripts. ASOs are designed to target the complementary sequence within a given RNA. Once delivered into the cell, they hybridize to the RNA complement by base pairing to specifically interfere with gene expression and inhibit protein production.
After alternate periods of success, antisense oligonucleotides have been recently resurrected mostly due to their more or less universally acknowledged role in the inhibition of gene expression, and the first antisense drug (Fomivirsen) has recently received FDA approval.
Antisense oligonucleotides against the majority of known oncogenes (c -myc, myb, mdm2) or anti-apoptotic genes have been experimentally tested in a series of human tumours. Treatment by oligo antisense against oncogenes inhibits the transformed phenotypes, while against antiapoptotic genes it increases apoptosis.
Oligonucleotide antisenses have been extensively used to inhibit HOX gene expression of tumour cells. The inhibition, by antisense oligonucleotides, of retinoic acid induced activation of 3' human HOX B genes (HOX B1 -HOX B3) in embryonic carcinoma cells, affects sequential activation of genes located upstream (with a 3' -to -5' polarity) in the four loci of the HOX network [68] . The targeted downregulation of MLL -AF9 gene (MLL gene is the corresponding gene in vertebrates of the Drosophila gene Tritorax) by antisense oligonucleotide reduces the expression of HOX A7 and HOX A10 genes and induces apoptosis in human leukemic cells [69] . Hox B3 transfection in fetal lung cells has been shown to increase retinol -induced gene expression of Clara -cell -specific secretory protein, while reducing the expression of surfectant-associated protein C. These alterations are attenuated by the transfection with Hox B3 antisense nucleotide.
However, satisfactory results in cancer treatment have so far not been obtained with the in vivo use of antisense oligonucleotides due to their fragility and toxicity, although there have been many successful in vitro examples, such as the ones we have described. To circumvent these problems, RNA interference using small double stranded siRNA (small interference RNA) has been applied.
RNA INTERFERENCE
RNA interference (RNAi) is a relatively new technology with the potential to investigate molecular physiology by means of specific and effective gene silencing both in vitro and in vivo. Short interfering RNAs are 21-23 base pairs double stranded RNA molecules with 2-nucleotide 3' overhangs (to increase stability) derived from the citoplasmic processing of long dsRNA by the RNase III type enzyme Dicer. siRNAs are similar to non coding RNA molecules called microRNA (miRNAs) naturally used by cells to regulate gene expression. They bind to the RISC complex, which promotes the cleavage of the RNA containing a particular sequence. A further way to generate siRNAs duplex is by synthetic short hairpin RNA (shRNA). The production of this synthetic shRNA is obtained from genetherapy vectors (either viral or nonviral) and it is an efficient means of experimentally eliciting RNAi in vivo. This mechanism leads to the virtual abolition of the expression of the target gene with almost absolute specificity. The selectivity conveyed by the gene sequence, which could potentially be as stringent as a single nucleotide difference between two genes, promises to aid in therapeutic approaches by providing much better target selectivity [70] . However significant drawbacks, such as incomplete suppression of target genes, non-specific immune response, in vivo delivery and the so-called off-target effects, either mediated by siRNA acting as a microRNA, or by the non-specific stress response of the cell need to be overcome before this technology can be successfully translated into clinical therapeutic practice. The fact that siRNAs are specifically and rapidly incorporated into RISC decreases the possibility of non-specific protein binding. A series of control experiments are required in order to minimize these risks. The lowest effective concentration of siRNA should be used, in therapy, to avoid aspecific gene silencing. Using siRNA to inhibit genes in vitro and in vivo has improved studies on the mechanism of action for many disease genes, including those involved in the angiogenic process. The capability of using siRNA in vivo to validate angiogenesis factors as drug targets is uniquely important, because its pathological impact can only be characterized accurately in animal disease models. siRNAs protect mice from fulminant hepatitis, viral infection, sepsis and tumour growth. With the emergence of clinically viable delivery vehicles, anti-angiogenesis RNAi agents appear to have a promising and unprecedented role for the treatment of many serious human diseases that result from excessive angiogenesis. Using this systemic delivery of siRNA targeting VEGF pathway factors at sites of neovascularization, anti-angiogenesis efficacies has been achieved in a neuroblastoma tumor model [71] . Furthermore siRNAs targeting human VEGF have been found to inhibit the secretion of VEGF in the human prostate cancer cell line PC-3 [72] . The siRNA approach for gene silencing holds great therapeutic promise, as siRNAs, like microRNAs, are naturally used by cells to regulate gene expression and are therefore non toxic and highly effective.
HOX genes and siRNA interference have only recently been coupled following the discovery of siRNA functionality in mammalian cells just a few years ago. Deregulation of HOX A9 by RNA interference decreases cell migration and tube formation of endothelial human cells suggesting that HOX A9 plays a role in endothelial cell migration and may exert its function by regulating the expression of EphB4 [73] . The oncogene Bmi1 stilulates H2A ubiquitylation for Hox gene silencing and normal cell growth. By RNA interference experiments it has been analyzed in vivo the role of Bmi1 in H2A ubiquitylation and Hox C5 gene expression. Knockdown of Bmi1 causes a global and loci-specific loss of H2A ubiquitylation, up-regulation of the Hox C5 gene, and slower cell growth [74] .
Very recently a new role has been proposed for RNAs: instead of turning off genes (RNAi), synthetic RNAs are able to activate target genes (RNAa) [75] . This finding (if confirmed) will reveal an increasing role for small RNA molecules in the regulation of gene expression compared to what has so far been recognized and could be very powerful, in terms of potential anticancer therapeutic applications.
CONCLUSIONS
The majority of genetic diseases are generated by the combined effect of mutations in a series of genes. In cancer, this process is known through the phenomenon of oncogene cooperation and often concerns the alteration of proteins involved in cell-cell signaling. Targeting these proteins in cancer therapy requires the correction of several protein alterations, which is difficult to achieve. In our view, the HOX gene network represents a complex gene system responsible for spatio-temporal cell localization as well as for decoding cell-cell signaling in order to achieve phenotype cell identity. It represents a sort of hardware where the cell memory is located and crucial cell functions are focused. Experimental evidence on HOX gene deregulation in human leukemias and in several types of human solid tumours (breast, prostate, kidney, bladder, lung, melanoma) has recently been produced. Here we propose to target the key genes of the HOX network, dysregulated in specific cancer phenotypes, in order to achieve a therapeutic effect through the use of antisense oligonucleotides and siRNAs.
However, future challenges for antisense therapy strategies still remain. These include: a) the further optimisation of the ASO chemical backbone to improve stability. b) optimisation of drug delivery c) the development of biologybased combinations of ASOs, d) the clinical evaluation and optimisation of short interfering RNA. Moreover, the finding that clinically successful small molecule inhibitors have more than one target and that cancer cells use multiple pathways to maintain their malignant phenotype challenges the fundamental concept of antisense therapy. However, unlike conventional cytotoxic agents for which specificity is important, there may be a significant advantage to less precise inhibitors based on the fact that cell signaling is not a linear process but rather involves a complex interplay of several often redundant pathways. In this respect, the HOX gene network might represent a particularly appealing target for antisense therapy.
